Show simple item record

dc.contributor.authorBoudewijns, S
dc.contributor.authorBol, KF
dc.contributor.authorSchreibelt, G
dc.contributor.authorWestdorp, H
dc.contributor.authorTextor, JC
dc.contributor.authorvan Rossum, MM
dc.contributor.authorScharenborg, NM
dc.contributor.authorde Boer, AJ
dc.contributor.authorvan de Rakt, MWMM
dc.contributor.authorPots, JM
dc.contributor.authorvan Oorschot, TGM
dc.contributor.authorDuiveman-de Boer, T
dc.contributor.authorOlde Nordkamp, MA
dc.contributor.authorvan Meeteren, WSEC
dc.contributor.authorvan der Graaf, WTA
dc.contributor.authorBonenkamp, JJ
dc.contributor.authorde Wilt, JHW
dc.contributor.authorAarntzen, EHJG
dc.contributor.authorPunt, CJA
dc.contributor.authorGerritsen, WR
dc.contributor.authorFigdor, CG
dc.contributor.authorde Vries, IJM
dc.date.accessioned2016-09-28T11:22:29Z
dc.date.issued2016-07
dc.identifier.citationOncoimmunology, 2016, 5 (7), pp. e1191732 - ?
dc.identifier.issn2162-4011
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/132
dc.identifier.eissn2162-402X
dc.identifier.doi10.1080/2162402x.2016.1191732
dc.description.abstractPurpose To determine the effectiveness of adjuvant dendritic cell (DC) vaccination to induce tumor-specific immunological responses in stage III melanoma patients.Experimental design Retrospective analysis of stage III melanoma patients, vaccinated with autologous monocyte-derived DC loaded with tumor-associated antigens (TAA) gp100 and tyrosinase after radical lymph node dissection. Skin-test infiltrating lymphocytes (SKILs) obtained from delayed-type hypersensitivity skin-test biopsies were analyzed for the presence of TAA-specific CD8(+) T cells by tetrameric MHC-peptide complexes and by functional TAA-specific T cell assays, defined by peptide-recognition (T2 cells) and/or tumor-recognition (BLM and/or MEL624) with specific production of Th1 cytokines and no Th2 cytokines.Results Ninety-seven patients were analyzed: 21 with stage IIIA, 34 with stage IIIB, and 42 had stage IIIC disease. Tetramer-positive CD8(+) T cells were present in 68 patients (70%), and 24 of them showed a response against all 3 epitopes tested (gp100:154-162, gp100:280-288, and tyrosinase:369-377) at any point during vaccinations. A functional T cell response was found in 62 patients (64%). Rates of peptide-recognition of gp100:154-162, gp100:280-288, and tyrosinase:369-377 were 40%, 29%, and 45%, respectively. Median recurrence-free survival and distant metastasis-free survival of the whole study population were 23.0 mo and 36.8 mo, respectively.Conclusions DC vaccination induces a functional TAA-specific T cell response in the majority of stage III melanoma patients, indicating it is more effective in stage III than in stage IV melanoma patients. Furthermore, performing multiple cycles of vaccinations enhances the chance of a broader immune response.
dc.formatElectronic-eCollection
dc.format.extente1191732 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleAdjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.
dc.typeJournal Article
dcterms.dateAccepted2016-05-15
rioxxterms.versionofrecord10.1080/2162402x.2016.1191732
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.licenseref.startdate2016-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfOncoimmunology
pubs.issue7
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.publication-statusPublished
pubs.volume5
pubs.embargo.termsNo embargo
icr.researchteamClinical and Translational Sarcomaen_US
dc.contributor.icrauthorvan der Graaf, Wilhelminaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0